Figure 1
Immunomax ® inhibits metastatic disease and prolongs the survival of 4T1 tumor-resected mice. (A) Experimental design. (B) Three injections of Immunomax® significantly decreased the number of clonogenic tumor cells in the lungs of mice (n = 8, control group; n = 9, Immunomax® injected group) determined on day 20 post-resection (*P < 0.05). (C) Continued weekly injections with Immunomax® until the 69th day significantly prolonged the survival of mice (***P < 0.0001, n = 14, control group; n = 22, Immunomax® injected group). Thirty one percent of mice from this group were completely cured from the disease. Survival curves were compared using the log rank test with GraphPad Prism.